BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 38141764)

  • 1. The glycoimmune checkpoint receptor Siglec-7 interacts with T-cell ligands and regulates T-cell activation.
    Stewart N; Daly J; Drummond-Guy O; Krishnamoorthy V; Stark JC; Riley NM; Williams KC; Bertozzi CR; Wisnovsky S
    J Biol Chem; 2024 Feb; 300(2):105579. PubMed ID: 38141764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9.
    Ikehara Y; Ikehara SK; Paulson JC
    J Biol Chem; 2004 Oct; 279(41):43117-25. PubMed ID: 15292262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colonic epithelial cells express specific ligands for mucosal macrophage immunosuppressive receptors siglec-7 and -9.
    Miyazaki K; Sakuma K; Kawamura YI; Izawa M; Ohmori K; Mitsuki M; Yamaji T; Hashimoto Y; Suzuki A; Saito Y; Dohi T; Kannagi R
    J Immunol; 2012 May; 188(9):4690-700. PubMed ID: 22467657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Siglec-5 is an inhibitory immune checkpoint molecule for human T cells.
    Vuchkovska A; Glanville DG; Scurti GM; Nishimura MI; White P; Ulijasz AT; Iwashima M
    Immunology; 2022 Jun; 166(2):238-248. PubMed ID: 35290663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7.
    Wisnovsky S; Möckl L; Malaker SA; Pedram K; Hess GT; Riley NM; Gray MA; Smith BAH; Bassik MC; Moerner WE; Bertozzi CR
    Proc Natl Acad Sci U S A; 2021 Feb; 118(5):. PubMed ID: 33495350
    [No Abstract]   [Full Text] [Related]  

  • 6. MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint.
    Smith BAH; Deutzmann A; Correa KM; Delaveris CS; Dhanasekaran R; Dove CG; Sullivan DK; Wisnovsky S; Stark JC; Pluvinage JV; Swaminathan S; Riley NM; Rajan A; Majeti R; Felsher DW; Bertozzi CR
    Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2215376120. PubMed ID: 36897988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early murine T-lymphocyte activation is accompanied by a switch from N-Glycolyl- to N-acetyl-neuraminic acid and generation of ligands for siglec-E.
    Redelinghuys P; Antonopoulos A; Liu Y; Campanero-Rhodes MA; McKenzie E; Haslam SM; Dell A; Feizi T; Crocker PR
    J Biol Chem; 2011 Oct; 286(40):34522-32. PubMed ID: 21835922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Siglec-7 tetramers characterize B-cell subpopulations and leukemic blasts.
    Gieseke F; Mang P; Viebahn S; Sonntag I; Kruchen A; Erbacher A; Pfeiffer M; Handgretinger R; Müller I
    Eur J Immunol; 2012 Aug; 42(8):2176-86. PubMed ID: 22585296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mouse Siglec-F and human Siglec-8 are functionally convergent paralogs that are selectively expressed on eosinophils and recognize 6'-sulfo-sialyl Lewis X as a preferred glycan ligand.
    Tateno H; Crocker PR; Paulson JC
    Glycobiology; 2005 Nov; 15(11):1125-35. PubMed ID: 15972893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor cell-intrinsic and tumor microenvironmental conditions co-determine signaling by the glycoimmune checkpoint receptor Siglec-7.
    van Houtum EJH; Kers-Rebel ED; Looman MW; Hooijberg E; Büll C; Granado D; Cornelissen LAM; Adema GJ
    Cell Mol Life Sci; 2023 May; 80(6):169. PubMed ID: 37253806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional evaluation of activation-dependent alterations in the sialoglycan composition of T cells.
    Naito-Matsui Y; Takada S; Kano Y; Iyoda T; Sugai M; Shimizu A; Inaba K; Nitschke L; Tsubata T; Oka S; Kozutsumi Y; Takematsu H
    J Biol Chem; 2014 Jan; 289(3):1564-79. PubMed ID: 24297165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Siglec Signaling in the Tumor Microenvironment.
    van Houtum EJH; Büll C; Cornelissen LAM; Adema GJ
    Front Immunol; 2021; 12():790317. PubMed ID: 34966391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B Cell Siglecs-News on Signaling and Its Interplay With Ligand Binding.
    Meyer SJ; Linder AT; Brandl C; Nitschke L
    Front Immunol; 2018; 9():2820. PubMed ID: 30559744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unraveling Molecular Recognition of Glycan Ligands by Siglec-9 via NMR Spectroscopy and Molecular Dynamics Modeling.
    Atxabal U; Nycholat C; Pröpster JM; Fernández A; Oyenarte I; Lenza MP; Franconetti A; Soares CO; Coelho H; Marcelo F; Schubert M; Paulson JC; Jiménez-Barbero J; Ereño-Orbea J
    ACS Chem Biol; 2024 Feb; 19(2):483-496. PubMed ID: 38321945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study of the asparagine-linked oligosaccharides on siglec-5, siglec-7 and siglec-8, expressed in a CHO cell line, and their contribution to ligand recognition.
    Freeman S; Birrell HC; D'Alessio K; Erickson-Miller C; Kikly K; Camilleri P
    Eur J Biochem; 2001 Mar; 268(5):1228-37. PubMed ID: 11231274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probing the cis interactions of the inhibitory receptor Siglec-7 with alpha2,8-disialylated ligands on natural killer cells and other leukocytes using glycan-specific antibodies and by analysis of alpha2,8-sialyltransferase gene expression.
    Avril T; North SJ; Haslam SM; Willison HJ; Crocker PR
    J Leukoc Biol; 2006 Oct; 80(4):787-96. PubMed ID: 16857734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GCNT1-Mediated
    Perkey E; Maurice De Sousa D; Carrington L; Chung J; Dils A; Granadier D; Koch U; Radtke F; Ludewig B; Blazar BR; Siebel CW; Brennan TV; Nolz J; Labrecque N; Maillard I
    J Immunol; 2020 Mar; 204(6):1674-1688. PubMed ID: 32060138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endogenous airway mucins carry glycans that bind Siglec-F and induce eosinophil apoptosis.
    Kiwamoto T; Katoh T; Evans CM; Janssen WJ; Brummet ME; Hudson SA; Zhu Z; Tiemeyer M; Bochner BS
    J Allergy Clin Immunol; 2015 May; 135(5):1329-1340.e9. PubMed ID: 25497369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "Siglec"ting the allergic response for therapeutic targeting.
    Bochner BS
    Glycobiology; 2016 Jun; 26(6):546-52. PubMed ID: 26911285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients.
    Benmerzoug S; Chevalier MF; Verardo M; Nguyen S; Cesson V; Schneider AK; Dartiguenave F; Rodrigues-Dias SC; Lucca I; Jichlinski P; Roth B; Nardelli-Haefliger D; Derré L
    Eur Urol Focus; 2022 May; 8(3):748-751. PubMed ID: 34147404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.